NIH Highlighted Topic: Advancing Mechanism-driven Translational Research of Beneficial and Detrimental Effect of Psilocybin on Cancer and Other Health Conditions
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing mechanism-driven translational research into both the beneficial and detrimental effects of psilocybin on cancer and other health conditions. This highlighted topic supports rigorous human-relevant studies designed to improve scientific understanding of psilocybin’s biological activity, therapeutic potential, safety profile, and long-term health impacts.
NIH is particularly interested in projects investigating molecular pathways, receptor interactions, biomarkers, pharmacology, neurobiology, and translational models that can inform future clinical trial design and evidence-based human use. Companies developing psychedelic therapeutics, AI-enabled biomarker platforms, digital therapeutics, neuropharmacology technologies, translational drug development systems, computational biology tools, or precision medicine platforms may be strong candidates for funding.
Areas of interest include psilocybin’s effects on cancer therapeutics, pain management, mental health, neuroplasticity, substance use disorders (SUDs), chronic use and microdosing, pharmacokinetics, host genetics, immune modulation, and interactions with standard-of-care therapies. NIH is also encouraging projects focused on novel psilocybin analogs, human-relevant disease models, AI-enabled analytics, and translational research technologies capable of improving therapeutic precision and risk mitigation.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by the National Cancer Institute (NCI), National Center for Complementary and Integrative Health (NCCIH), and National Institute on Drug Abuse (NIDA), all of which are seeking transformative innovations that improve understanding, safety, therapeutic development, and evidence-based use of psilocybin and related compounds.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of psychedelic therapeutics, translational research technologies, biomarkers, computational tools, and precision medicine systems related to psilocybin research.
Eligible activities may include:
Psilocybin therapeutic development and translational drug discovery
AI and machine learning platforms for psychedelic biomarker analysis
Neuropharmacology and neuroplasticity research technologies
Precision medicine and patient stratification systems
Clinical decision support and dosing optimization platforms
Human-relevant disease models and translational research systems
Computational biology and systems pharmacology tools
Biomarker discovery and predictive analytics technologies
Pain management and symptom burden intervention platforms
Substance use disorder (SUD) therapeutic development technologies
Psilocybin analog, prodrug, and modified compound development
Pharmacokinetic and safety profiling technologies
Digital therapeutics and behavioral intervention integration systems
Immune, tumor, and neurological response analysis platforms
Cancer symptom management and supportive care technologies
Longitudinal monitoring systems for chronic use and microdosing studies
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, medicinal chemistry, AI model development, software engineering, cloud infrastructure, clinical trial preparation, bioinformatics analysis, preclinical studies, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable biotechnology or therapeutic solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
